Boehringer Ingelheim and IdeaSphere announce acquisition deal
Pharmaton business will be taken over by the American health care specialist
"IdeaSphere has been carefully selected as a result of a diligent process and will be the ideal partner to further develop Pharmaton, while Boehringer Ingelheim will continue to strengthen its Consumer Healthcare business by further building up the flagship and international core brands, e.g. Dulcolax, Buscopan or Antistax", said Dr Alessandro Banchi, Chairman of the Board of Managing Directors at Boehringer Ingelheim and responsible for Marketing and Sales. "Both Pharmaton and IdeaSphere have a common strategic vision and core competencies in the development, production and marketing of natural health and multivitamin products", Banchi said. "IdeaSphere´s commitment supports the sustainability of the Lugano site and opens future growth opportunities for its management and employees."
All three parties emphasized on the further development and expansion of the Pharmaton business and company. Synergistic effects would not come by downsizing or cost cutting, but by market expansion and a good complementary product portfolio. The location Lugano would be further strengthened by adding new capacities to establish it as a center of excellence for R&D, Manufacturing and Marketing of Natural Health & Multivitamin Products.
IdeaSphere will take over the whole Pharmaton business and brands. Both companies agreed about a cooperation to toll-manufacture specific products of the respective company. To facilitate the transfer of the Pharmaton business BI will continue to distribute the Pharmaton products for a transitional period.
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.